Athanasios Spirakis
Effective October 11, 2023, we have appointed Mr. Athanasios Spirakis as a member of our Board of Directors.
Highest-materiality recent filing
Medinotec shareholders unanimously elect directors and ratify auditor at 2025 annual meeting
All five director nominees (Vizirgianakis, van Niekerk, Vizirgianakis, Dwyer, Spirakis) elected with 9,955,835 votes FOR each, zero against or abstain.
Medinotec announces 2024 annual meeting of stockholders for Feb 19, 2025
Virtual meeting on Feb 19, 2025 at 9:30 am ET; record date Dec 5, 2024.
Medinotec dismisses BDO South Africa as auditor, cites material internal control weaknesses
Dismissed BDO South Africa Inc. and engaged Mercurius & Associates LLP as auditor effective July 8, 2024.
Shareholders reject auditor BDO South Africa; all directors elected
Directors elected unopposed: each received 10,205,752 votes FOR.
Meeting held virtually via videoconference; no in-person attendance. Record date January 10, 2024; 11,733,750 common shares outstanding.
Medinotec appoints Athanasios Spirakis to Board and Audit Committee
Appointed effective October 11, 2023; Spirakis will serve as independent director and audit committee member.
Medinotec replaces auditor with BDO; reports material weaknesses in internal controls
Dismissed Mercurius & Associates and engaged BDO South Africa as new independent auditor on June 20, 2023.
Medinotec CFO discusses North American expansion, Trachealator FDA approval
CFO Pieter van Niekerk interviewed on products, North American expansion, and diversification plans.
Medinotec Inc. approved to trade on OTCQX Best Market under symbol MDNC
OTC Markets notified Medinotec on March 30, 2023; trading on OTCQX began March 31, 2023.
Medinotec assigned OTC ticker symbol MDNC; intends to upgrade to OTCQX
FINRA notified Medinotec common stock may trade OTC under symbol MDNC effective March 21, 2023.
Medinotec confirms recovery of $2.6M from SVB after FDIC backstop
Had $2.6M (96% of $2.7M cash) at Silicon Valley Bank, largely uninsured.
Medinotec files first audited financials: $720K revenue, $289K net loss for 9 months
Revenue $720,339, gross profit $420,197, net loss $289,077 for nine months ended Nov 30, 2022.
Medinotec reports first positive EBITDA of $58,553, revenue up 15% ahead of OTCQX listing
First positive quarterly EBITDA of $58,553 for quarter ended Nov 30, 2022.
Effective October 11, 2023, we have appointed Mr. Athanasios Spirakis as a member of our Board of Directors.
Max materiality 0.70 · Median 0.40 · Most common event other_material